CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,708 enrolled
Drug / intervention
EDTA +3 moredrug
Likely dose
EDTA: 40 infusions of standard chelation solution; High Dose Vitamin supplementationAI-extracted
Key inclusion· 1
  • ✓Prior myocardial infarction at least 6 weeks before enrollment
Key exclusion· 12
  • ✕Serum creatinine >2.0 mg/dL
  • ✕Platelet count <100,000/µL
  • ✕Blood pressure >160/100 mmHg
  • ✕Prior chelation therapy within 5 years

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00044213
NCT00044213Phase 3Completed
CompareCT.gov

Trial to Assess Chelation Therapy (TACT)

Mt. Sinai Medical Center, Miami·interventional·Posted Aug 23, 2002·Updated Nov 5, 2013

In Brief

A Phase 3 clinical trial evaluating EDTA, EDTA Placebo, and 2 other interventions for Coronary Artery Disease. Completed, enrolled 1,708 participants across 86 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesCanada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH)

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2002
Enrollment StartSep 1, 2003
Primary CompletionOct 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 23.9 years ago

Interventions

EDTAdrug

Participants will receive 40 infusions of standard chelation solution.

EDTA Placebodrug

Participants will receive 40 infusions of EDTA placebo.

High Dose Vitamindietary

High Dose Vitamin Placebodietary